Thrombolytic Therapy in Acute Ischemic Stroke Study, Part A "TTAISS"

Completed

Phase 2 Results

Eligibility Criteria

Inclusion Criteria

Acute ischemic stroke presenting within 6 hours of onset, measurable neurological deficit, aged 18-79.

Exclusion Criteria

Coma, minor or rapidly improving stroke symptoms, history of stroke within previous 6 weeks, known active seizure disorder or seizure within 6 hours of study drug administration, previous known intracranial hemorrhage, neoplasm, subarachnoid hemorrhage arteriovenous malformation, or aneurysm, clinical presentation suggestive of subarachnoid hemorrhage, hypertension, presumed septic embolus, presumed pericarditis or presence of ventricular thrombus or aneurysm related to recent acute myocardial infarction, surgery or trauma within previous 30 days, head trauma within previous 90 days, active or recent hemorrhage, known hereditary or acquired hemorrhagic diathesis, pregnancy, lactation or parturition within previous 30 days, abnormal lab values, other serious, advanced or terminal illness, current participation in trial of another research drug.